Long-Term Outcomes Following Sirolimus-Coated Balloon or Drug-Eluting Stents for Treatment of In-Stent Restenosis
Wojciech Wańha,Sylwia Iwańczyk,Rafał Januszek,Rafał Wolny,Brunon Tomasiewicz,Wiktor Kuliczkowski,Krzysztof Reczuch,Paweł Pawlus,Tomasz Z. Pawłowski,Łukasz Kuźma,Piotr Kubler,Piotr Niezgoda,Jacek Kubica,Robert J. Gil,Tomasz F. Pawłowski,Mariusz Gąsior,Miłosz Jaguszewski,Maciej Wybraniec,Adam Witkowski,Mariusz Kowalewski,Fabrizio D'Ascenzo,Antonio Greco,Stanisław Bartuś,Maciej Lesiak,Marek Grygier,Wojciech Wojakowski,Bernardo Cortese
DOI: https://doi.org/10.1161/circinterventions.124.014064
2024-07-27
Circulation Cardiovascular Interventions
Abstract:Circulation: Cardiovascular Interventions, Ahead of Print. BACKGROUND:Evidence suggests that drug-coated balloons may benefit in-stent restenosis (ISR) treatment. However, the efficacy of new-generation sirolimus-coated balloon (SCB) compared with the latest generation drug-eluting stents (DESs) has not been studied in this setting.METHODS:All patients in the EASTBORNE (The All-Comers Sirolimus-Coated Balloon European Registry) and DEB-DRAGON (DEB vs Thin-DES in DES-ISR: Long Term Outcomes) registries undergoing percutaneous coronary intervention for DES-ISR were included in the study. The primary study end point was target lesion revascularization at 24 months. Secondary end points were major adverse cardiovascular events, all-cause death, myocardial infarction, and target vessel revascularization at 24 months. Our goal was to evaluate the efficacy and safety of SCB versus thin-struts DES in ISR at long-term follow-up.RESULTS:A total of 1545 patients with 1679 ISR lesions were included in the pooled analysis, of whom 621 (40.2%) patients with 621 lesions were treated with thin-strut DES and 924 (59.8%) patients with 1045 lesions were treated with SCB. The unmatched cohort showed no differences in the incidence of target lesion revascularization (10.8% versus 11.8%;P=0.568); however, there was a trend toward lower rates of myocardial infarction (7.4% versus 5.0%;P=0.062) and major adverse cardiovascular events (20.8% versus 17.1%;P=0.072) in the SCB group. After propensity score matching (n=335 patients per group), there were no significant differences in the rates of target lesion revascularization (11.6% versus 11.8%;P=0.329), target vessel revascularization (14.0% versus 13.1%;P=0.822), myocardial infarction (7.2% versus 4.5%;P=0.186), all-cause death (5.7% versus 4.2%;P=0.476), and major adverse cardiovascular event (21.5% versus 17.6%;P=0.242) between DES and SCB treatment.CONCLUSIONS:In patients with ISR, angioplasty with SCB compared with thin-struts DES is associated with comparable rates of target lesion revascularization, target vessel revascularization, myocardial infarction, all-cause death, and major adverse cardiovascular events at 2 years.
cardiac & cardiovascular systems